Cargando…

VEGF with AMD3100 endogenously mobilizes mesenchymal stem cells and improves fracture healing

A significant number of fractures develop non‐union. Mesenchymal stem cell (MSC) therapy may be beneficial, however, this requires cell acquisition, culture and delivery. Endogenous mobilization of stem cells offers a non‐invasive alternative. The hypothesis was administration of VEGF and the CXCR4...

Descripción completa

Detalles Bibliográficos
Autores principales: Meeson, Richard, Sanghani‐Keri, Anita, Coathup, Melanie, Blunn, Gordon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6563072/
https://www.ncbi.nlm.nih.gov/pubmed/30345545
http://dx.doi.org/10.1002/jor.24164
_version_ 1783426467553607680
author Meeson, Richard
Sanghani‐Keri, Anita
Coathup, Melanie
Blunn, Gordon
author_facet Meeson, Richard
Sanghani‐Keri, Anita
Coathup, Melanie
Blunn, Gordon
author_sort Meeson, Richard
collection PubMed
description A significant number of fractures develop non‐union. Mesenchymal stem cell (MSC) therapy may be beneficial, however, this requires cell acquisition, culture and delivery. Endogenous mobilization of stem cells offers a non‐invasive alternative. The hypothesis was administration of VEGF and the CXCR4 antagonist AMD3100 would increase the circulating pool of available MSCs and improve fracture healing. Ex‐breeder female wistar rats received VEGF followed by AMD3100, or sham PBS. Blood prepared for culture and colonies were counted. P3 cells were analyzed by flow cytometry, bi‐differentiation. The effect of mobilization on fracture healing was evaluated with 1.5 mm femoral osteotomy stabilized with an external fixator in 12–14 week old female Wistars. The mobilized group had significantly greater number of cfus/ml compared to controls, p = 0.029. The isolated cells expressed 1.8% CD34, 35% CD45, 61% CD29, 78% CD90, and differentiated into osteoblasts but not into adipocytes. The fracture gap in animals treated with VEGF and AMD3100 showed increased bone volume; 5.22 ± 1.7 µm(3) and trabecular thickness 0.05 ± 0.01 µm compared with control animals (4.3 ± 3.1 µm(3), 0.04 ± 0.01 µm, respectively). Radiographic scores quantifying fracture healing (RUST) showed that the animals in the mobilization group had a higher healing score compared to controls (9.6 vs. 7.7). Histologically, mobilization resulted in significantly lower group variability in bone formation (p = 0.032) and greater amounts of bone and less fibrous tissue than the control group. Clinical significance: This pre‐clinical study demonstrates a beneficial effect of endogenous MSC mobilization on fracture healing, which may have translation potential to prevent or treat clinical fractures at risk of delayed or non‐union fractures. © 2018 The Authors. Journal of Orthopaedic Research® Published by Wiley Periodicals, Inc. on behalf of Orthopaedic Research Society. J Orthop Res 37:1294–1302, 2019.
format Online
Article
Text
id pubmed-6563072
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-65630722019-06-17 VEGF with AMD3100 endogenously mobilizes mesenchymal stem cells and improves fracture healing Meeson, Richard Sanghani‐Keri, Anita Coathup, Melanie Blunn, Gordon J Orthop Res Research Articles A significant number of fractures develop non‐union. Mesenchymal stem cell (MSC) therapy may be beneficial, however, this requires cell acquisition, culture and delivery. Endogenous mobilization of stem cells offers a non‐invasive alternative. The hypothesis was administration of VEGF and the CXCR4 antagonist AMD3100 would increase the circulating pool of available MSCs and improve fracture healing. Ex‐breeder female wistar rats received VEGF followed by AMD3100, or sham PBS. Blood prepared for culture and colonies were counted. P3 cells were analyzed by flow cytometry, bi‐differentiation. The effect of mobilization on fracture healing was evaluated with 1.5 mm femoral osteotomy stabilized with an external fixator in 12–14 week old female Wistars. The mobilized group had significantly greater number of cfus/ml compared to controls, p = 0.029. The isolated cells expressed 1.8% CD34, 35% CD45, 61% CD29, 78% CD90, and differentiated into osteoblasts but not into adipocytes. The fracture gap in animals treated with VEGF and AMD3100 showed increased bone volume; 5.22 ± 1.7 µm(3) and trabecular thickness 0.05 ± 0.01 µm compared with control animals (4.3 ± 3.1 µm(3), 0.04 ± 0.01 µm, respectively). Radiographic scores quantifying fracture healing (RUST) showed that the animals in the mobilization group had a higher healing score compared to controls (9.6 vs. 7.7). Histologically, mobilization resulted in significantly lower group variability in bone formation (p = 0.032) and greater amounts of bone and less fibrous tissue than the control group. Clinical significance: This pre‐clinical study demonstrates a beneficial effect of endogenous MSC mobilization on fracture healing, which may have translation potential to prevent or treat clinical fractures at risk of delayed or non‐union fractures. © 2018 The Authors. Journal of Orthopaedic Research® Published by Wiley Periodicals, Inc. on behalf of Orthopaedic Research Society. J Orthop Res 37:1294–1302, 2019. John Wiley and Sons Inc. 2018-11-30 2019-06 /pmc/articles/PMC6563072/ /pubmed/30345545 http://dx.doi.org/10.1002/jor.24164 Text en © 2018 The Authors. Journal of Orthopaedic Research1® Published by Wiley Periodicals, Inc. on behalf of Orthopaedic Research Society. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
Meeson, Richard
Sanghani‐Keri, Anita
Coathup, Melanie
Blunn, Gordon
VEGF with AMD3100 endogenously mobilizes mesenchymal stem cells and improves fracture healing
title VEGF with AMD3100 endogenously mobilizes mesenchymal stem cells and improves fracture healing
title_full VEGF with AMD3100 endogenously mobilizes mesenchymal stem cells and improves fracture healing
title_fullStr VEGF with AMD3100 endogenously mobilizes mesenchymal stem cells and improves fracture healing
title_full_unstemmed VEGF with AMD3100 endogenously mobilizes mesenchymal stem cells and improves fracture healing
title_short VEGF with AMD3100 endogenously mobilizes mesenchymal stem cells and improves fracture healing
title_sort vegf with amd3100 endogenously mobilizes mesenchymal stem cells and improves fracture healing
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6563072/
https://www.ncbi.nlm.nih.gov/pubmed/30345545
http://dx.doi.org/10.1002/jor.24164
work_keys_str_mv AT meesonrichard vegfwithamd3100endogenouslymobilizesmesenchymalstemcellsandimprovesfracturehealing
AT sanghanikerianita vegfwithamd3100endogenouslymobilizesmesenchymalstemcellsandimprovesfracturehealing
AT coathupmelanie vegfwithamd3100endogenouslymobilizesmesenchymalstemcellsandimprovesfracturehealing
AT blunngordon vegfwithamd3100endogenouslymobilizesmesenchymalstemcellsandimprovesfracturehealing